BioAtla (BCAB)

• Market cap: $12.1M
• 1 day: 9.06%
• 5 days: -42.73%
• 1 month: -55.55%
• 3 months: -71.55%
• 6 months: -42.99%
• Year to date: -64.62%
• 1 year: -58.38%
• 5 years: -99.59%
• 10 years: -99.39%
• Sector: Healthcare
• Industry: Biotechnology

About: BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

Employees: 61